← All trials
NCT05680155
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Oct 21, 2024
- Completion date
- Oct 21, 2024
- First posted
- Jan 11, 2023
- Last posted
- Jul 17, 2023
- Enrollment
- 211
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sciwind Biosciences APAC CO Pty. Ltd.Lead sponsor
- Nanjing UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.